Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?

There is an urgent need for new therapies to treat non-small cell lung cancer (NSCLC), as progress with current chemotherapy regimens has been limited. The roles of vascular endothelial growth factor (VEGF) in promoting tumor angiogenesis, maintaining existing vasculature, and contributing to resistance to traditional therapies, together with its negative prognostic significance in NSCLC, make it an appropriate target for therapy. Bevacizumab (Avastin; Genentech Inc., South San Francisco, CA), a monoclonal antibody directed against VEGF, has shown promise in treating a number of different cancers. In a recent phase II trial in patients with advanced metastatic NSCLC, the addition of bevacizumab to standard carboplatin/paclitaxel chemotherapy produced a significantly longer time to progression (32.1 versus 18.4 weeks) and greater response rate (31% versus 19% [not significant]) than chemotherapy alone. In the subset of patients with nonsquamous histologies, response rates and survival were further enhanced, with a mean survival time of 17.9 months versus 12.3 months with chemotherapy alone. Bevacizumab was generally well tolerated and did not appear to increase the incidences or severities of the nausea/vomiting, neuropathy, and renal toxicity that are typically associated with carboplatin/paclitaxel chemotherapy. Adverse events in phase I and II studies included hypertension, thrombosis, proteinuria (with occasional nephrotic syndrome), and epistaxis. Serious tumor-related bleeding episodes (hemoptysis/hematemesis) appear to be the main safety concern in patients with NSCLC, with squamous cell histology as a possible risk factor. Further work is needed to identify the best way to use bevacizumab in NSCLC, including use in combination with other biologic agents and in the adjuvant setting.

[1]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[2]  N. Ferrara Vascular endothelial growth factor as a target for anticancer therapy. , 2004, The oncologist.

[3]  Helen X. Chen Expanding the clinical development of bevacizumab. , 2004, The oncologist.

[4]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[5]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[6]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[7]  J. Harmey,et al.  Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[8]  L. Rosen Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[9]  Robert C Brasch,et al.  Dynamic contrast‐enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti‐angiogenic therapy in a xenograft model of glioblastoma multiforme , 2002, Journal of magnetic resonance imaging : JMRI.

[10]  A. Nicholson,et al.  Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas , 2002, British Journal of Cancer.

[11]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[12]  E. Galligioni,et al.  Angiogenesis and antiangiogenic agents in non-small cell lung cancer. , 2001, Lung cancer.

[13]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[14]  M. Toi,et al.  Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. , 2001, The Lancet. Oncology.

[15]  A. Giatromanolaki Prognostic role of angiogenesis in non-small cell lung cancer. , 2001, Anticancer research.

[16]  K. Sugimachi,et al.  High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. , 2001, Lung cancer.

[17]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[18]  D. Hicklin,et al.  Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. , 2001, Cancer research.

[19]  J. Crowley,et al.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Sledge,et al.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. , 2001, Cancer research.

[21]  G. Sledge,et al.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Voest,et al.  The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. , 2001, Seminars in oncology.

[23]  J. Breed,et al.  Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Yuan,et al.  Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Hansen,et al.  Non-small-cell lung cancer--stalemate or progress? , 2000, The New England journal of medicine.

[26]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[27]  M. Dewhirst,et al.  Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. , 2000, Journal of the National Cancer Institute.

[28]  Cherrington,et al.  SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.

[29]  A. Harris,et al.  Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.

[30]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[31]  R. Henriksson,et al.  Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Henriksson,et al.  p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma , 2000, International journal of cancer.

[33]  D. Carbone,et al.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[35]  O. Melnyk,et al.  Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. , 1999, The Journal of urology.

[36]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[37]  Megumi Baba,et al.  Anti‐tumor and anti‐metastatic effects of human‐vascular‐endothelial‐growth‐factor‐neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice , 1998, International journal of cancer.

[38]  J. Foekens,et al.  Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Sugimura,et al.  Antitumor Effect of a Neutralizing Antibody to Vascular Endothelial Growth Factor on Liver Metastasis of Endocrine Neoplasm , 1998, Japanese journal of cancer research : Gann.

[40]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[41]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[42]  O. Vinante,et al.  Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. , 1997, Journal of the National Cancer Institute.

[43]  M. Volm,et al.  Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. , 1996, British Journal of Cancer.

[44]  S. Hirota,et al.  Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[45]  G. Viglietto,et al.  Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. , 1995, Oncogene.

[46]  Anthony J. Guidi,et al.  Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. , 1995, Journal of the National Cancer Institute.

[47]  M. Toi,et al.  Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer , 1994, Japanese journal of cancer research : Gann.

[48]  B. Teicher,et al.  Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents , 1994, International journal of cancer.

[49]  E. Manseau,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.

[50]  E. Manseau,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.

[51]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[52]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[53]  G. Sledge,et al.  Angiogenesis and antiangiogenic therapy. , 2002, Current problems in cancer.

[54]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[55]  N. Ferrara,et al.  Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis , 1999 .

[56]  N. van Bruggen,et al.  Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. , 1998, Cancer investigation.

[57]  Anthony J. Guidi,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.

[58]  S. Ramakrishnan,et al.  Vascular permeability factor gene expression in normal and neoplastic human ovaries. , 1994, Cancer research.

[59]  W. Reinhold,et al.  Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. , 1993, The Journal of clinical investigation.